324 related articles for article (PubMed ID: 20121565)
1. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.
McGinn D; Godman B; Lonsdale J; Way R; Wettermark B; Haycox A
Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):73-85. PubMed ID: 20121565
[TBL] [Abstract][Full Text] [Related]
2. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.
Bennie M; Godman B; Bishop I; Campbell S
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):125-30. PubMed ID: 22280202
[TBL] [Abstract][Full Text] [Related]
3. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.
Godman B; Burkhardt T; Bucsics A; Wettermark B; Wieninger P
Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):475-84. PubMed ID: 19817531
[TBL] [Abstract][Full Text] [Related]
4. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi.
Abuelkhair M; Abdu S; Godman B; Fahmy S; Malmström RE; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):115-24. PubMed ID: 22280201
[TBL] [Abstract][Full Text] [Related]
5. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.
Fraeyman J; Van Hal G; Godman B; Beutels P
Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):141-51. PubMed ID: 23402454
[TBL] [Abstract][Full Text] [Related]
6. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions.
Markovic-Pekovic V; Skrbić R; Godman B; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):661-71. PubMed ID: 23186404
[TBL] [Abstract][Full Text] [Related]
7. Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.
Godman B; Bishop I; Campbell SM; Malmström RE; Truter I
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):323-30. PubMed ID: 25338546
[TBL] [Abstract][Full Text] [Related]
8. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications.
Woerkom Mv; Piepenbrink H; Godman B; Metz Jd; Campbell S; Bennie M; Eimers M; Gustafsson LL
J Comp Eff Res; 2012 Nov; 1(6):527-38. PubMed ID: 24236472
[TBL] [Abstract][Full Text] [Related]
9. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction.
Coma A; Zara C; Godman B; Agustí A; Diogène E; Wettermark B; Haycox A
Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):569-81. PubMed ID: 19941434
[TBL] [Abstract][Full Text] [Related]
10. Prescribing efficiency of proton pump inhibitors in China: influence and future directions.
Zeng W; Finlayson AE; Shankar S; de Bruyn W; Godman B
BMC Health Serv Res; 2015 Jan; 15():11. PubMed ID: 25609265
[TBL] [Abstract][Full Text] [Related]
11. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs.
Godman B; Sakshaug S; Berg C; Wettermark B; Haycox A
Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):121-9. PubMed ID: 21351864
[TBL] [Abstract][Full Text] [Related]
12. European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703
[TBL] [Abstract][Full Text] [Related]
13. Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications.
Leporowski A; Godman B; Kurdi A; MacBride-Stewart S; Ryan M; Hurding S; Do Nascimento RC; Bennie M; Morton A
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):655-666. PubMed ID: 30014725
[TBL] [Abstract][Full Text] [Related]
14. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists' effect on prescribing practice at a tertiary hospital.
Luo H; Fan Q; Xiao S; Chen K
BMC Health Serv Res; 2018 Jul; 18(1):537. PubMed ID: 29996830
[TBL] [Abstract][Full Text] [Related]
15. Initiatives in South Africa to enhance the prescribing of generic proton pump inhibitors: findings and implications.
Truter I; Shankar S; Bennie M; Woerkom Mv; Godman B
J Comp Eff Res; 2015 Mar; 4(2):123-31. PubMed ID: 25825841
[TBL] [Abstract][Full Text] [Related]
16. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries.
Godman B; Bucsics A; Burkhardt T; Schmitzer M; Wettermark B; Wieninger P
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):199-207. PubMed ID: 20384566
[TBL] [Abstract][Full Text] [Related]
17. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
[TBL] [Abstract][Full Text] [Related]
18. Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.
Bennie M; Bishop I; Godman B; Barbui C; Raschi E; Campbell S; Miranda J; Gustafsson LL
Int J Clin Pract; 2013 Feb; 67(2):170-80. PubMed ID: 23305478
[TBL] [Abstract][Full Text] [Related]
19. The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013.
Fuksa L; Vocelka M; Vytrisalova M
Health Policy; 2015 Sep; 119(9):1255-64. PubMed ID: 25929214
[TBL] [Abstract][Full Text] [Related]
20. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications.
Godman B; Shrank W; Andersen M; Berg C; Bishop I; Burkhardt T; Garuoliene K; Herholz H; Joppi R; Kalaba M; Laius O; McGinn D; Samaluk V; Sermet C; Schwabe U; Teixeira I; Tilson L; Tulunay FC; Vlahović-Palčevski V; Wendykowska K; Wettermark B; Zara C; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):707-22. PubMed ID: 21155704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
